{"id":82960,"date":"2021-03-09T22:59:34","date_gmt":"2021-03-09T14:59:34","guid":{"rendered":"https:\/\/www.chinapulse.com\/?p=185401"},"modified":"2021-03-09T22:59:34","modified_gmt":"2021-03-09T14:59:34","slug":"eirion-therapeutics-inc-closes-40-million-series-a-investment-and-licensing-deal-with-shanghai-haohai-biological-technology-ltd","status":"publish","type":"post","link":"https:\/\/www.chinalegalblog.com\/en\/2021\/03\/09\/eirion-therapeutics-inc-closes-40-million-series-a-investment-and-licensing-deal-with-shanghai-haohai-biological-technology-ltd\/","title":{"rendered":"Eirion Therapeutics, Inc. Closes $40 Million Series A Investment and Licensing Deal with Shanghai Haohai Biological Technology Ltd."},"content":{"rendered":"<p>WOBURN, Mass. , March 9, 2021 \/PRNewswire\/ &#8212; Today, Eirion Therapeutics, Inc., an aesthetic dermatology company headquartered in Woburn, Massachusetts , announced a deal with Shanghai Haohai Biological Technology Ltd. (&#8220;Haohai&#8221;) that will result in a $32 million Series A Preferred Stock investment into Eirion along with exclusive licenses that will be for all of Eirion&#8217;s products for the territory of China in exchange for an upfront payment in the amount of $8 million .&#8230;<\/p>\n<p>This data comes from the <a href=\"https:\/\/www.chinapulse.com\/\" title=\"ChinaPulse.com provides Media Intelligence and Media Monitoring in China\" >ChinaPulse.com media intelligence and smart news insights monitoring platform<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>WOBURN, Mass. , March 9, 2021 \/PRNewswire\/ &#8212; Today, Eirion Therapeutics, Inc., an aesthetic dermatology company headquartered in Woburn, Massachusetts , announced a deal with Shanghai Haohai Biological Technology Ltd. (\"Haohai\") that &#8230;<\/p>\n","protected":false},"author":250,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[144,213,339,477,1607,288,194,494,401,1542,1623],"tags":[10417,3472,10391,10315,10341,7004],"class_list":["post-82960","post","type-post","status-publish","format-standard","hentry","category-china","category-china-news","category-hong-kong","category-investment","category-manufacturing","category-medicine","category-news-chinese-law","category-pharmaceutical","category-shanghai","category-technology","category-venture-capital","tag-alcoholic-beverage","tag-chinese","tag-florida","tag-media-intelligence","tag-seafood","tag-shipping"],"_links":{"self":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts\/82960","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/users\/250"}],"replies":[{"embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/comments?post=82960"}],"version-history":[{"count":1,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts\/82960\/revisions"}],"predecessor-version":[{"id":82961,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts\/82960\/revisions\/82961"}],"wp:attachment":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/media?parent=82960"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/categories?post=82960"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/tags?post=82960"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}